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Pituitary Tumor Transforming Gene 1 in the Liver
To the Editor:
We read with interest and appreciate the paper by Fujii et al.,1 but
feel it is necessary to make the following observations.
Despite advances in our cellular and molecular knowledge, hepa-
tocellular carcinoma (HCC) remains one of the major public health
problems throughout the world. It is now known to be highly hetero-
geneous as it encompasses various pathological entities and a wide
range of clinical behaviors, and is underpinned by a complex array of
gene alterations that affect supra-molecular processes.2
Pituitary tumour transforming gene 1 (PTTG-1) is an oncogene
expressed in various human neoplasms and cell lines.3-8 Although its
pathogenetic implications in HCC are still unknown, it has been
shown that its over-expression in hepatoma cell lines negatively regu-
lates the ability of p53 to induce apoptosis, and that its silencing by
means of short interference RNA may be an efﬁcient way of treating
liver cancer.8
The expression of tumor-associated antigens is mainly investigated
at the gene level by means of quantitative real-time PCR (qrt-PCR).
However, the information provided by this approach is limited by the
fact that the phenomena observed at each level of anatomical organi-
zation (i.e., genes, sub-cellular entities, cells, tissues, organs, appara-
tuses and organisms) have properties that do not exist at lower or
higher levels: qrt-PCR offers an adequate quantitative description of
small-scale structures, but this is likely to be inapplicable when it comes
to large-scale features.9
We used an immunoperoxidase-based staining assay to investigate
the expression of PTTG-1 (anti-PTTG-1 polyclonal antibodies,
Zymed Laboratory Inc., San Francisco, CA) in liver tissues taken from
patients affected by chronic HCV-related hepatitis and primary HCC,
and found that there were four immunopositive cell types: (a) hepato-
cytes recognized in hepatitic tissue in which the protein was located
near the biliary pole (Fig. 1A); (B) Kupffer cells identiﬁed in hepatic
tissue and surrounding the cancerous lesion (Fig. 1B); (c) some T
lymphocytes situated in the portal spaces (Fig. 1C); and (d) a propor-
tion of neoplastic liver cells (Fig. 1D). Primary colon cancer tissues
were used as a positive control (Fig. 1E), and tissues incubated with
rabbit immunoglobulin fraction (Dako, Milan, Italy) as a negative
control (Fig. 1F).
All of our ﬁndings demonstrate broader PTTG-1 expression in the
liver than that reported by Fujii et al.1 Furthermore, on the basis of the
above microscopic observations, it is possible to say:
1. The qrt-PCR detection of mRNA encoding PTTG-1 in HCC
tissue and the surrounding non-cancerous hepatic parenchyma does
not distinguish the cell types expressing the protein or its relative
quantitative contribution to the total amount of detected mRNA.
2. The presence of PTTG-1 in tumoral and non-tumoral cells may
actually be considered a shared characteristic that makes it possible to
group different cell types in a single category.
3. The detection of PTTG-1 expression in some intrahepatic T
lymphocytes extends previous ﬁndings showing its enhanced expres-
sion in circulating activated T cells.10
In conclusion, the paper of Fujii et al. discusses important points
but, although the clinical application seems to be remarkable, we and
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Fig. 1. PTTG-1 expression immuno-recognition in hepatocytes, in
which the protein was located near the biliary pole (A), macrophagic
Kupffer cells (B), some T lymphocytes sited in the portal spaces (C), and
in a proportion of cancer liver cells (D). Primary colon cancer tissues were
used as a positive control (E); exempliﬁcative HCC tissue incubated with
rabbit immunoglobulin fraction used as a negative control (F) (Objective
magniﬁcation: A: 40; B: 10; C-F: 20; inset: 63).
1701
7. Heaney AP, Singson R,McCabe CJ, Nelson V, NakashimaM,Melmed S.
Expression of pituitary-tumour transforming gene in colorectal tumours.
Lancet 2000;355:716-719.
8. Jung CR, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, et al. Adenovirus-
mediated transfer of siRNA against PTTG1 inhibits liver cancer cell
growth in vitro and in vivo. HEPATOLOGY 2006;43:1042-1052.
9. Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W. Cancer immu-
notherapy: avoiding the road to perdition. J Transl Med 2004;2:26.
10. Stoika R, Melmed S. Expression and function of pituitary tumour trans-
forming gene for T-lymphocyte activation. Br J Haematol
2002;119:1070-1074.
Copyright © 2006 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.002.hep.21428
Potential conﬂict nothing to report.
1702 CORRESPONDENCE HEPATOLOGY, December 2006
